Copenhagen - Delayed Quote DKK

Coloplast A/S (COLO-B.CO)

Compare
794.80
+1.60
+(0.20%)
At close: December 27 at 4:59:47 PM GMT+1
Loading Chart for COLO-B.CO
DELL
  • Previous Close 793.20
  • Open 792.00
  • Bid 794.80 x --
  • Ask 796.60 x --
  • Day's Range 791.60 - 807.00
  • 52 Week Range 757.80 - 977.60
  • Volume 123,227
  • Avg. Volume 172,917
  • Market Cap (intraday) 179.096B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 35.34
  • EPS (TTM) 22.49
  • Earnings Date Feb 4, 2025
  • Forward Dividend & Yield 22.00 (2.77%)
  • Ex-Dividend Date Dec 6, 2024
  • 1y Target Est 924.43

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

www.coloplast.com

16,639

Full Time Employees

September 30

Fiscal Year Ends

Recent News: COLO-B.CO

View More

Performance Overview: COLO-B.CO

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

COLO-B.CO
5.62%
OMX Copenhagen 25 Index
1.32%

1-Year Return

COLO-B.CO
4.75%
OMX Copenhagen 25 Index
0.00%

3-Year Return

COLO-B.CO
25.22%
OMX Copenhagen 25 Index
6.89%

5-Year Return

COLO-B.CO
6.16%
OMX Copenhagen 25 Index
0.00%

Compare To: COLO-B.CO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: COLO-B.CO

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    179.10B

  • Enterprise Value

    200.94B

  • Trailing P/E

    35.39

  • Forward P/E

    29.76

  • PEG Ratio (5yr expected)

    2.93

  • Price/Sales (ttm)

    6.61

  • Price/Book (mrq)

    9.98

  • Enterprise Value/Revenue

    7.43

  • Enterprise Value/EBITDA

    23.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.69%

  • Return on Assets (ttm)

    9.49%

  • Return on Equity (ttm)

    28.67%

  • Revenue (ttm)

    27.03B

  • Net Income Avi to Common (ttm)

    5.05B

  • Diluted EPS (ttm)

    22.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    788M

  • Total Debt/Equity (mrq)

    126.12%

  • Levered Free Cash Flow (ttm)

    -647.75M

Research Analysis: COLO-B.CO

View More

People Also Watch